Protected: Retina Global: “Our goal is to train the people on the ground to obtain a sustainable outcome”
Retina Global sends retina specialists to parts of the world having a great need for expert eye care. “It is always our goal to have a sustainable outcome”, CEO Rajat Agrawal says.
Pravin Dugel, M.D.: “Biological signal for efficacy of THR-149”
“As an investigator of THR-149, I was encouraged to see the results from its clinical phase 1 trial", Pravin Dugel, M.D., says.
Phase 1 trial showed THR-149 is a highly potent plasma kallikrein inhibitor to treat DME
In 2019, Oxurion announced positive topline data for the compound THR-149, a highly potent plasma kallikrein inhibitor to treat diabetic macular edema (DME).
Arshad Khanani: “Initial data of phase 1 trial of THR-687 point to clinical efficacy”
Arshad Khanani, M.D., M.A. about the clinical phase 1 data of THR-687.
Positive phase 1 data indicate THR-687 could be an effective therapy for patients with DME
Oxurion kick-started 2020 with positive topline data from phase 1 clinical trial evaluating THR-687 for treatment of DME.
A strategic focus for Oxurion: researching and developing non-VEGF pathways
Jean Feyen, PhD., Chief Scientific Officer, and Andy De Deene, M.D., Global Head of Development, explain why Oxurion decided to focus on non-VEGF pathways.
Oxurion NV Partners with Prevent Blindness to Educate Public on Diabetes-related Eye Disease
Both Oxurion and Prevent Blindness join forces during November to educate the public on risk factors, symptoms, treatment options, and financial assistance resources.
3 reasons why we need to raise diabetic eye disease awareness
Diabetic eye diseases affect millions of people globally, and still there's a high unmet need in diagnosis and treatment. It's high time to get the message across to risk groups.
Creating Diabetic Eye Disease Awareness with Prevent Blindness
This November, in support of Diabetic Eye Disease Awareness Month, Oxurion is partnering with Prevent Blindness and its sight saving efforts.
Alan Stitt: “We need therapies fighting different hallmarks simultaneously”
PDR and DME are two manifestations of diabetic retinopathy (DR), and in many respects they stem from the same cause, explains professor Alan Stitt.
Rajat Agrawal: “Join forces to fight eye disease in developing countries”
“In those parts of the world there are many patients who lack access to routine retinal care,” Dr. Agrawal explains. “We aim to provide clinical care by sending retina ...
“JETREA has a group of very loyal users worldwide”
Vinciane Vangeersdaele joined the Oxurion leadership team this past year. With extensive experience in commercializing pharmaceutical portfolios worldwide, including in ...
“Oxurion remains innovator in novel retinal therapies”
“There is currently an explosion in R&D activities in the retinal space. Numerous potential new therapies are ready for translation into clinical studies, making this a truly ...